Troubled pharma company Celgene (CELG) posted Q2 results beating analysts’ view and also lifted its earnings outlook for 2018. Shares of Celgene rose about 2% before the bell and continued the positive momentum when the market opened today. Celgene’s total revenue grew 17% year-over-year to $3.81 billion on strong Revlimid sales growth of 21%. GAAP … Continue reading Celgene stock rises on upbeat Q2 results, lifts outlook